Loss of striatal dopaminergic terminals during the early stage in response to MPTP injection in C57BL/6 mice

Neuroscience Research

Volumn 69, Issue 4, 2011, Pages 352-355

  Muroyama, Akiko ^a   Kobayashi, Shota ^a   Mitsumoto, Yasuhide ^a  

^a HOKURIKU UNIVERSITY   (Japan)

Author keywords

Dopamine transporter; Immunoisolation; Mouse model; MPTP; Striatal dopaminergic terminal

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINO ACID; DOPAMINE TRANSPORTER; VANOXERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CELL FRACTIONATION; CELL FREE SYSTEM; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; MALE; MOUSE; NERVE CELL NECROSIS; NERVE ENDING; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; SYNAPTOSOME;

ANIMALS; BLOTTING, WESTERN; CORPUS STRIATUM; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; PRESYNAPTIC TERMINALS; SYNAPTOSOMES;

EID: 79951941413     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2010.12.009     Document Type: Article

References (32)

1. Arai N., Misugi K., Goshima Y., Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res. 1990, 515:57-63.
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
3. Bougria M., Vitorica J., Cano J., Machado A. Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes. Eur. J. Pharmacol. 1995, 291:407-415.
4. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:4546-4550.
5. Cochiolo J.A., Ehsanian R., Bruck D.K. Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: evidence of compensatory plasticity in nigrostriatal neurons. J. Neurosci. Res. 2000, 59:126-135.
6. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
7. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 2004, 185:232-240.
8. Galvin J.E., Uryu K., Lee V.M., Trojanowski J.Q. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13450-13455.
9. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
10. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311:467-469.
11. + within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 1991, 40:133-158.
12. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:2173-2177.
13. 1H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice. Eur. J. Neurosci. 2006, 23:1077-1081.
14. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
15. Li H., Li S.H., Yu Z.X., Shelbourne P., Li X.J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 2001, 21:8473-8481.
16. Li L.H., Qin H.Z., Wang J.L., Wang J., Wang X.L., Gao G.D. Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Int. Med. Res. 2009, 37:455-463.
17. Mallajosyula J.K., Kaur D., Chinta S.J., Rajagopalan S., Rane A., Nicholls D.G., Di Monte D.A., Macarthur H., Andersen J.K. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One 2008, 3:e1616.
18. Mandir A.S., Przedborski S., Jackson-Lewis V., Wang Z.Q., Simbulan-Rosenthal C.M., Smulson M.E., Hoffman B.E., Guastella D.B., Dawson V.L., Dawson T.M. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:5774-5779.
19. 10 prevents cytochrome c release from mitochondria induced by 1-methyl-4-phenylpyridinium ion in mouse brain synaptosomes. Neurosci. Lett. 2009, 463:22-25.
20. Mizuno Y., Saitoh T., Sone N. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem. Biophys. Res. Commun. 1987, 143:971-976.
21. Morfini G., Pigino G., Opalach K., Serulle Y., Moreira J.E., Sugimori M., Llinás R.R., Brady S.T. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:2442-2447.
22. +) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Deltapsi(m)) in rat striatum. Exp. Neurol. 2003, 179:103-110.
23. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985, 36:2503-2508.
24. Raff M.C., Whitmore A.V., Finn J.T. Axonal self-destruction and neurodegeneration. Science 2002, 296:868-871.
25. Ramsay R.R., Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 1986, 261:7585-7587.
26. Saha A.R., Hill J., Utton M.A., Asuni A.A., Ackerley S., Grierson A.J., Miller C.C., Davies A.M., Buchman V.L., Anderton B.H., Hanger D.P. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci. 2004, 117:1017-1024.
27. Saporito M.S., Thomas B.A., Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 2000, 75:1200-1208.
28. Speciale S.G. MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol. Teratol. 2002, 24:607-620.
29. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., Raman R., Davies P., Masliah E., Williams D.S., Goldstein L.S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307:1282-1288.
30. Sundström E., Fredriksson A., Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res. 1990, 528:181-188.
31. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 1993, 61:1191-1206.
32. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:2837-2842.